Klaris

Name: Klaris
Brand: Klaris

Klaris is a B2B software platform that performs automated pre-submission regulatory review of medical device Technical Documentation by clause-by-clause gap assessment against an expert requirement library and cross-document consistency checks, producing structured, clause-linked findings with suggested remediation actions.

Website

Published Sep 19, 2026

01Common complaints

- If a full eQMS / design control system is the primary requirement - For organizations whose primary need is CAPA management, training, audits, design history file management, or change control workflows, an eQMS-first solution may be more appropriate. - If abundant independent third-party reviews are required prior to procurement - Public third-party review presence for the vendor was limited in the materials retrieved; procurement teams that rely heavily on review-platform validation should account for this. - If transparent self-serve pricing and rapid procurement are required - The vendor does not publish pricing in the retrieved materials, which may slow procurement for teams with constrained budgets. - If regulatory intelligence and registration management are the central bottleneck - For needs focused on market registrations, UDI/EUDAMED workflows, or regulatory-change surveillance, a RIM/regulatory management tool may be a better fit. - If the organization cannot commit to human review/validation of AI outputs - The outputs produced by automated reviewers should be validated by regulatory professionals; organizations expecting fully autonomous accuracy risk compliance issues. - Current limitations acknowledged in vendor materials - The vendor specifies that it does not draft new documents, does not make intended-use determinations, does not perform clinical evaluations, does not replace regulatory authorities, and does not issue certifications. - Roadmap / future coverage - The vendor indicates plans to extend coverage (for example, broader 510(k) coverage indicated for future development) but specific timelines and deliverables were not detailed in the reviewed materials. - Security/compliance disclosure gaps - While ISO/IEC 27001:2022 certification is reported, other enterprise procurement artifacts (SOC 2 Type II reports, pen-test summaries, detailed SSO/SCIM/audit log feature lists) were not publicly documented in the materials reviewed. - Access to the vendor Trust Center could not be validated in this research session; buyers should request a full sub-processor list and control scope during diligence. - Market visibility / name collision risk - The vendor name is subject to search collisions with unrelated products and community content; procurement teams should confirm entity identity when conducting diligence.

Deal disqualifiers (poor fit)

Teams seeking a full eQMS replacement.
Teams expecting full auto-drafting of new documents rather than gap identification and suggested remediation.
Extremely novel device categories where the vendor's requirement library may require significant customization.

02Why they buy

- Vendor-claimed differentiators (not independently verified in third-party reviews) - Traceability - The vendor states that each finding is linked to the exact clause, paragraph, or document location. - Reproducibility and grounding approach - The vendor describes its approach as mapping source text to a library of expert-authored requirements to reduce spurious or ungrounded outputs. - Cross-document drift detection - The product includes functionality to identify contradictions across CER, IFU, and risk-management files. - Data handling posture - The vendor states it does not use customer data to train models and describes contractual limitations on data retention with external model providers. - Areas where competitors may be stronger - eQMS vendors typically provide deeper workflow controls, audit artifacts, and integrations that support end-to-end quality processes. - RIM vendors generally provide broader registration management and regulatory intelligence coverage.

03Field reports

Review platforms (Gartner Peer Insights, G2, TrustRadius)

No clear product pages for the vendor were found on major review platforms in the retrieved results; searches returned similarly named products in some cases, which may create discovery risk.

Vendor-published testimonials (summarized; vendor-hosted, not independently verified)

- Vendor-cited testimonial: A customer reported that the product identified multiple potential nonconformities shortly before submission. - Vendor-cited testimonial: A regulatory manager commented on the perceived technical competence of the system. - Vendor-cited testimonial: A user described the platform as simple and understandable to operate. - These testimonials are hosted on vendor pages and were not corroborated by independent third-party reviews in the material reviewed here.

Community / social discussions (relevance and noise)

Public forum search results for the vendor name frequently returned unrelated items (name collisions), which can make independent feedback harder to locate for procurement teams.
A Product Hunt announcement and several forum posts referenced the product launch or related projects, but detailed independent user evaluations were not found in the retrieved set.

Why customers said they chose the vendor (inferred from vendor messaging)

Traceability of findings to clause and document location.
Cross-document consistency checking across clinical evaluation reports (CER), instructions for use (IFU), and risk files.
Reduction of manual reviewer time spent on mechanical checks.
These are primarily vendor-stated reasons; independent validation was not located in the sources reviewed.

Why some customers might leave (inferred from market patterns)

Expectations mismatches when customers expect full drafting/authoring rather than gap identification and remediation suggestions.
Redundancy with existing mature eQMS or RIM systems if integrations are limited.
The vendor's pricing approach may be a barrier for smaller firms compared with lower-cost or internally managed processes.

Klaris-specific case studies

No detailed, independently verifiable case studies with methodology and third-party confirmation were identified in the retrieved materials. The vendor provides testimonials that include outcome-like statements but lack methodological detail.

Analogous case evidence (for benchmarking only)

Independent case studies from other providers indicate that platform-assisted reviews can yield measurable speed improvements in document QA workflows; such benchmarks are illustrative and do not demonstrate vendor-specific performance.

Methodology questions to raise during diligence

How are the requirement statements authored, versioned, and validated?
How are novel or borderline regulatory scenarios handled (e.g., new technologies, combination products, SaMD with AI components)?
What are measured false positive and false negative rates on representative datasets?
Can exported artifacts (traceability matrices, full finding lists) be produced for audit purposes?

04Best fit

Company sizes

Likely fit: small-to-mid-market MedTech firms (tens to a few hundred employees) preparing EU MDR submissions, where reviewer cycles are a primary bottleneck.
Larger enterprises could adopt the product if it integrates effectively with existing QMS/RIM stacks.

Industries and verticals

Medical device manufacturers, including software as a medical device (SaMD) and AI-enabled products preparing EU MDR documentation.

Roles and personas

Decision makers: heads of Regulatory Affairs, VPs of Quality/Regulatory Affairs, PRRCs, Directors of Clinical/Regulatory.
End users: regulatory affairs specialists, CER authors, risk file owners, and labeling/IFU maintainers.

Pain points addressed

Identification of late-stage nonconformities and reviewer questions prior to external submission.
Cross-document inconsistencies between CER, IFU, and risk files.
Reducing manual mechanical checking time for senior RA/QA staff.

Qualification criteria (good fit)

Technical files are sufficiently mature that gap findings and consistency detection provide actionable remediation work.
The organization can allocate regulatory/quality resources to adjudicate suggested remediations.

05The pitch

What the product does (core value proposition in objective terms)

- Klaris is a B2B software platform that performs automated pre-submission regulatory review of medical-device Technical Documentation (TD). - It focuses on two primary functions: - Clause-by-clause gap assessment against an expert-authored requirement library (the Klaris "Regulatory Reviewer"). - Cross-document consistency checks to detect discrepancies and contradictions between files (the Klaris "Consistency Reviewer"). - The output is a structured report where each identified gap is linked to a specific clause and location in the submitted documents, with proposed remediation suggestions. - Klaris states that it does not replace a Notified Body or FDA review, does not issue certification or approval, and does not make regulatory judgment calls such as intended-use determinations or clinical evaluations.

Target market and market positioning

Primary users are MedTech and medical device manufacturers focused on preparing technical files for EU MDR and related submissions.
The product is positioned to identify gaps and inconsistencies earlier in the documentation lifecycle to reduce late-stage findings and reviewer follow-up.

Get a comprehensive analysis of Klaris including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →